Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect
(By Madhav Thambisetty for STAT) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover
Read More
Aducanumab
An Alzheimer’s drug is on the way, but getting it may still be tough. Here’s why
(By Jon Hamilton for NPR) The first drug shown to slow down Alzheimer’s disease is likely to receive full approval
Read More